News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Hepatitis C Drug Wins Backing From UK's National Institute for Clinical Excellence (NICE)



3/16/2012 7:37:31 AM

Johnson & Johnson (JNJ)’s Incivo won the backing of the U.K.’s health-cost regulator in a draft recommendation for the treatment of hepatitis C. The medicine, also known as telaprevir or Incivek, is a cost-effective option for chronically infected hepatitis C patients when used with older drugs peginterferon alfa and ribavirin, the National Institute for Health and Clinical Excellence said today in a statement. The agency advises the state-run National Health Service on which products represent value for money.

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES